Various tumor types such as colorectal cancer, ovarian cancer, and pancreatic ductal adenocarcinoma (PDAC; refs. 10–12) often present with high TGF-β signaling, which might be another barrier to effective combinatorial immunotherapy (13–15). This evidence concerns the gene TGFB1 and neoplasm.